Compounding Pharmacy: 5 Red Flags to Avoid

Affiliate disclosure: This article contains affiliate links. We may earn commission when you purchase through partner links, at no extra cost to you. Editorial independence preserved — recommendations based on provider compliance and patient outcomes, not commission rates. This article is informational and is not medical advice.

A compounded GLP-1 can be a legitimate, lower-cost route to treatment — but a compounded medication is only as good as the pharmacy that prepares it. Unlike an FDA-approved product, a compounded preparation has not been through the FDA’s review for safety, effectiveness and quality; the pharmacy itself is the safeguard. That makes verifying the pharmacy your job, and in 2026 — with the regulatory landscape for compounded GLP-1s tightening — it matters more than ever. The good news is that a compounding pharmacy can be checked, concretely, in a few steps. This guide walks through them.

503A or 503B — Know Which Pharmacy You’re Dealing With

Before you verify anything, know which of two categories the pharmacy falls into, because they are regulated differently.

A 503A pharmacy is a traditional compounding pharmacy. It prepares medications for individual patients against a specific prescription written for that person, and it is licensed and overseen primarily by its state board of pharmacy. When a telehealth platform arranges compounded semaglutide for you personally, a 503A pharmacy is almost always the one filling it.

A 503B outsourcing facility operates at larger scale. It registers directly with the FDA, must follow current good manufacturing practice (cGMP) standards, is subject to FDA inspection, and typically supplies clinics and hospitals in bulk rather than filling individual prescriptions. The FDA keeps a public list of registered 503B facilities.

Two things are worth knowing. First, for an individual patient buying compounded medication through telehealth, the 503A pathway is the normal route — a clinician writes your prescription, a state-licensed pharmacy compounds it. Second, appearing on the FDA’s 503B registered list is not by itself a guarantee of quality: registration is not the same as a recent, satisfactory inspection, and a number of registered facilities have inspection findings on record. The category tells you which rules apply; it does not end the verification.

Step One — Verify the State License

Every legitimate compounding pharmacy holds a license from the board of pharmacy in its home state — and if it ships to you across state lines, it generally also needs a non-resident (or out-of-state) license from your state’s board. This is the legal floor, and it is checkable.

State boards of pharmacy maintain public license lookups on their websites. You can search the pharmacy by name and confirm two things: that it holds a current, active license, and that the license is in good standing rather than under disciplinary action. A legitimate pharmacy will also disclose its license number on request, and often publicly. If a pharmacy will not tell you what it is licensed as, or in which states, treat that as an answer in itself.

The non-resident piece is easy to overlook and worth checking specifically: a pharmacy fully licensed in its own state may still not be licensed to ship to yours. Your own state’s board of pharmacy is where to confirm that the pharmacy can legally dispense to you.

One more public record is worth a minute: the FDA’s warning-letter database. The FDA publishes enforcement actions and inspection findings against compounding pharmacies and outsourcing facilities, and a history of serious, unresolved problems — sterility failures, contamination, corrections a facility never completed — is a meaningful signal that a state license lookup will not show you. Searching the pharmacy’s name there is a quick, worthwhile cross-check.

Step Two — Look for PCAB Accreditation

State licensing is the minimum. PCAB accreditation is the quality signal layered on top of it.

PCAB — the Pharmacy Compounding Accreditation Board, now operated under the Accreditation Commission for Health Care — is a voluntary accreditation specifically for compounding pharmacies. Earning it means a pharmacy has passed an on-site survey conducted by surveyors who are themselves compounding pharmacists, against standards aligned with the United States Pharmacopeia’s compounding chapters. Accreditation is not one-and-done: pharmacies undergo ongoing reverification to keep it.

The distinction is worth holding onto. A state license confirms a pharmacy meets the minimum legal requirements to operate. PCAB accreditation confirms it has volunteered for independent, expert-level scrutiny of how it actually compounds. Not every legitimate compounding pharmacy carries it, so its absence alone is not proof of a problem — but its presence is a genuine, verifiable mark that a pharmacy has opened its compounding practices to outside expert review. A pharmacy that holds PCAB accreditation will say so plainly; it should be able to show its accreditation, and the accreditor itself lists the pharmacies that hold it.

Step Three — The GLP-1-Specific Questions

Two checks matter specifically for compounded semaglutide and tirzepatide, and they are where some of the real risk has surfaced.

The first is where the active ingredient comes from. A legitimate compounder sources its semaglutide or tirzepatide as a bulk drug substance from an FDA-registered facility — properly documented starting material. The danger sign is active ingredient described as “research grade” or “for research use only.” The FDA has warned specifically about semaglutide and tirzepatide sold under that labeling: it sits outside the regulated supply, its quality is unknown, and no legitimate pharmacy compounds patient medication from it. A related issue surfaced during the shortage period, when some compounders used salt forms of semaglutide — semaglutide sodium or acetate — that the FDA flagged as not the same as the form in the approved drugs. A legitimate pharmacy can tell you exactly which form of the drug it dispenses.

The second is sterility. Injectable medication has to be compounded under sterile conditions — the governing standard is USP Chapter <797> for sterile preparations, with USP <795> covering non-sterile compounding. A pharmacy preparing injectable GLP-1s should be equipped and accredited for sterile compounding specifically; not every compounding pharmacy is. It is a fair and direct question to ask.

Red Flags That End the Conversation

Some signs mean stop, regardless of how the rest looks.

• It won’t name itself. If you cannot find out which pharmacy is actually compounding your medication, you cannot verify any of the above. A legitimate operation is identifiable.
• No prescription, no clinician. Compounding is, by definition, done against a prescription written for an individual patient. A site that will sell a compounded GLP-1 with no clinical evaluation is not operating legally.
• “Research use only” anywhere. On the product, the vial or the website, this labeling is a signal the material is not intended for human use.
• A price far below every legitimate option. Properly sourced, properly compounded medication has a real cost floor. A price that undercuts everything else is a warning, not a deal.
• Overseas shipping or untraceable payment. A pharmacy shipping from an unnamed facility abroad, or asking for payment by crypto, wire transfer or gift card, sits outside US oversight and outside your recourse.
• Vagueness as a pattern. One unanswered question might be an oversight. A pharmacy consistently vague about its license, its accreditation, its drug source and its compounding partner is telling you something.

Frequently Asked Questions

What is the difference between a 503A and a 503B pharmacy?

A 503A pharmacy is a traditional compounding pharmacy: it prepares medication for an individual patient against a specific prescription and is overseen mainly by its state board of pharmacy. A 503B outsourcing facility works at larger scale, registers with the FDA, follows cGMP manufacturing standards, and supplies clinics in bulk. For a patient getting compounded semaglutide through telehealth, the 503A route is the usual one.

How do I check if a compounding pharmacy is licensed?

Use your state board of pharmacy’s public license lookup, and the home state’s board as well. Search the pharmacy by name and confirm the license is current, active and in good standing. Check specifically that it holds a non-resident license for your state if it is shipping to you from elsewhere — a pharmacy licensed in its own state is not automatically cleared to dispense into yours.

Is PCAB accreditation required for a compounding pharmacy?

No — PCAB accreditation is voluntary. A state license is the requirement; PCAB is an additional, independent quality check on top of it. Many legitimate compounding pharmacies hold it and many do not, so its absence is not by itself a red flag — but its presence is a verifiable signal that the pharmacy has passed expert-level scrutiny of its compounding practices.

Is compounded semaglutide from a verified pharmacy safe?

Compounded semaglutide prepared by a properly licensed 503A pharmacy against an individual prescription is used by large numbers of people. It is still not an FDA-approved product, so it has not been through the agency’s review — which is exactly why verifying the pharmacy, and using one with clinician oversight, is what makes the route as safe as it can be. Verification reduces risk; it does not turn a compounded preparation into an FDA-approved one.

Is compounded semaglutide still legal now that the shortage is over?

Yes. The 503A pathway — a state-licensed pharmacy compounding a medication against a prescription written for an individual patient — is legal independent of whether a drug is on the FDA shortage list. What changed when the semaglutide shortage ended is the large-scale route: the FDA proposed in April 2026 to close 503B bulk compounding of these drugs. Patient-specific 503A compounding, the route most telehealth platforms use, remains in place — though the environment is contested, which is one more reason to use a pharmacy you have verified.

The Bottom Line

The compounded route can be entirely legitimate — but because a compounded medication has not been through FDA review, the pharmacy behind it carries the safety, and that pharmacy is something you can actually check. Know whether it is a 503A or 503B operation; confirm its state license, including a non-resident license for your state; look for PCAB accreditation as a quality signal; ask where the active ingredient comes from and whether it is equipped for sterile compounding; and walk away from the red flags — no named pharmacy, no prescription, “research” labeling, impossibly low prices. For the wider question of choosing a safe online seller, see our guide on buying GLP-1s online safely; for what the route costs, our 2026 GLP-1 cost guide.

Regulatory details in this article reflect the situation as of May 2026 and are evolving. This article is general information, not legal or medical advice; verify current licensing and discuss treatment with a licensed clinician.